The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCAwild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC):Exploratory analysis from a phase II study of CHK1i...
[5]Zhao Y, Zhang L, Ding Y, et al.Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J ...
Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overriding AraC resistance in AML remains an unmet medical need. Here we show that the CHK1 inhibitor (CHK1i) GDC-0575 enhances AraC-mediated killing of AML cel
We hypothesized that the Chk1 inhibitor MK-8776 increases the radiosensitivity of TNBC by inhibiting autophagy. Thus, we detected autophagy in TNBC cells using TEM, a StubRFP-SensGFP-LC3 lentivirus and Western blotting. Our results showed that irradiation can cause significant autophagic changes and ...
3.1. Determination of the experimental conditions using the MK-8776 inhibitor in APL and AML cells To explore the impact of CHK1 inhibition on cell proliferation and viability, we evaluated the MK-8776 inhibitor in three different types of AML cell lines: one ATRA-responsive cell line (NB4),...
The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the activity of CHK1i in platinum-resistant high-grade serous ovarian carcinoma (HGSOC) with ...
It is interesting to note that all Chk1 inhibitors so far tested in combination clinical trials (seven to date) have undergone clinical testing in combination with gemcitabine (ClinicalTrials.gov) whilst pemetrexed, cisplatin, irinotecan or cytarabine have been tested with only one Chk1 inhibitor ...
Chk2 Inhibitor Chk1 coordinates the DNA damage response (DDR) and cell cycle checkpoint response. Search 5-Fu-Based Doublet Program within People Getting Perioperative or perhaps Postoperative Radiation treatment Posted onOctober 13, 2024 Reply
While several DDR inhibitors offer great promise for future clinical applications, some have failed in early stages of clinical trials. For example, a phase I trial of Chk1 inhibitor AZD7762 with irinotecan in glioblastoma was stopped because of toxicity reports (NCT00473616). To overcome the ...
4.Samik Upadhaya et al. Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nature Reviews Drug Discovery.2022 Feb 10. 5.PD-(L)1临床开发挑战与机遇:近5000项临床试验联合疗法超8成.医药经理人.2022年2月13日....